Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01

Serge Belanger, an analyst from Needham, maintained the Buy rating on Oculis Holding. The associated price target remains the same with $40.00.

Serge Belanger has given his Buy rating due to a combination of factors tied to Oculis’s lead asset, OCS-01, and its late-stage clinical progress. He views the completion of last patient visits in the two Phase 3 DIAMOND studies as a key de-risking event ahead of the June topline readout, since success would position OCS-01 as the first topical therapy for diabetic macular edema and broaden treatment options beyond current anti-VEGF injections.

Belanger also notes that OCS-01 leverages the company’s OPTIREACH technology to deliver dexamethasone effectively to both the front and back of the eye, supporting its potential to serve patients insufficiently controlled on standard care as well as untreated patients. Anchored by prior dexamethasone experience in DME, encouraging Stage 1 DIAMOND data, and an estimated 75% probability of Phase 3 success that could unlock a market many times larger than Ozurdex’s roughly $200 million in U.S. sales, he reiterates a Buy rating and a $40 price target.

Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Esperion, and Cormedix. According to TipRanks, Belanger has an average return of 12.0% and a 48.90% success rate on recommended stocks.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $44.00 price target.